z-logo
Premium
THE DETERMINANTS OF PRICING IN PHARMACEUTICALS: ARE US PRICES REALLY SO HIGH?
Author(s) -
Cabrales Antonio,
JiménezMartín Sergi
Publication year - 2013
Publication title -
health economics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.55
H-Index - 109
eISSN - 1099-1050
pISSN - 1057-9230
DOI - 10.1002/hec.2887
Subject(s) - key (lock) , business , economics , list price , monetary economics , commerce , public economics , industrial organization , finance , computer science , computer security , real estate
SUMMARY This paper studies price determination in pharmaceutical markets using data for 25 countries, 6 years, and a comprehensive list of products from the MIDAS IMS database. A key finding is that the USA has prices that are not significantly higher than those of countries with similar income levels, especially those that are ‘lightly regulated’. More importantly, price differences to the US levels increase for ‘branded’, world top selling, or innovative products, and decrease, regardless of the level of regulation for mature or widely diffused molecules. Because prices for top selling molecules may be easier to perceive and recollect and more important for companies, they may bias the public discussion about international price differences. Copyright © 2013 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here